They found that patients with high Decipher Prostate scores received greater benefit from the addition of PLNRT and STADT to PBRT, compared to those with low genomic test scores. “The addition ...

(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025 held in Lugano, Switzerland was host to a session addressing the contemporary management of biochemically ...

The findings demonstrate the market leadership of its Decipher tests in better informing treatment decisions for patients with prostate and ... and how our GRID, or Genomic Resource for ...

ERG positivity, an early molecular alteration in prostate cancer development, exhibits differing prevalence between African American and White patients. Nevertheless, the extent of race-based ...

Scientists have uncovered new genetic clues that explain why some prostate cancers remain slow-growing while others become life-threatening.

Veracyte VCYT shares have surged 45.6% in the past year, showing impressive momentum. It has significantly outperformed the industry’s 7.6% fall and the S&P 500 composite’s gain of 8.8%. Presently ...

This marked Veracyte's tenth consecutive quarter of testing revenue growth at or above 20%, driven by its core diagnostic tools, Afirma and Decipher. Veracyte's prostate cancer genomic test ...